… By treating cells grown in microtiter plates with cell-permeable small molecules, and by
arraying the resulting lysates, Sevecka and MacBeath showed that compounds could be …

Although EGFR is a validated therapeutic target across multiple cancer indications, the
often modest clinical responses to current anti-EGFR agents suggest the need for improved …

As an alternative to conventional, target-oriented drug discovery, we report a strategy that
identifies compounds on the basis of the state that they induce in a signaling network. …

One of the principal challenges in systems biology is to uncover the networks of protein−protein
interactions that underlie most biological processes. To date, experimental efforts …

Targeted therapies have shown significant patient benefit in about 5–10% of solid tumors
that are addicted to a single oncogene. Here, we explore the idea of ligand addiction as a …

Although many anticancer drugs that target receptor tyrosine kinases (RTKs) provide clinical
benefit, their long-term use is limited by resistance that is often attributed to increased …

Receptor tyrosine kinases (RTKs) process extracellular cues by activating a broad array of
signaling proteins. Paradoxically, they often use the same proteins to elicit diverse and even …

Lysate microarrays (reverse-phase protein arrays) hold great promise as a tool for systems-level
investigations of signaling and multiplexed analyses of disease biomarkers. To date, …

A system-wide analysis of cell signaling requires detecting and quantifying many different
proteins and their posttranslational modification states in the same cellular sample. Here, we …

MM-121/SAR 256212 is a fully human anti ErbB3/HER3 antibody that blocks ligand-induced
receptor activation. Formation of EGFR/ErbB3 (ErbB1-3) heterodimers has been implicated …